GlaxoSmithKline and Alphabet Create $715 Million Bioelectronics Firm

636056475429290830untitled.png

01 Aug 2016 --- GlaxoSmithKline have announced an agreement with Verily Life Sciences LLC, an Alphabet company, to form Galvani Bioelectronics to enable the research, development and commercialisation of bioelectronic medicines. GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.

Galvani Bioelectronics will be headquartered in the UK, with the parent companies contributing existing intellectual property rights and an investment of up to $715 million over seven years, subject to successful completion of various discovery and development milestones.

Bioelectronic medicine is a relatively new scientific field that aims to tackle a wide range of chronic diseases using miniaturised, implantable devices that can modify electrical signals that pass along nerves in the body, including irregular or altered impulses that occur in many illnesses. GSK has been active in this field since 2012 and believes certain chronic conditions such as arthritis, diabetes and asthma could potentially be treated using these devices.

The agreement to establish Galvani Bioelectronics represents an important next step in GSK’s bioelectronics research. The new company will bring together GSK’s world class drug discovery and development expertise and deep understanding of disease biology with Verily’s world leading technical expertise in the miniaturisation of low power electronics, device development, data analytics and software development for clinical applications. Initial work will centre on establishing clinical proofs of principle in inflammatory, metabolic and endocrine disorders, including type 2 diabetes, where substantial evidence already exists in animal models; and developing associated miniaturised, precision devices.

Moncef Slaoui, GSK’s Chairman of Global Vaccines, who was instrumental in establishing GSK’s investments in the field of bioelectronics, will chair the board of the new company. He said:

“Many of the processes of the human body are controlled by electrical signals firing between the nervous system and the body’s organs, which may become distorted in many chronic diseases. Bioelectronic medicine’s vision is to employ the latest advances in biology and technology to interpret this electrical conversation and to correct the irregular patterns found in disease states, using miniaturised devices attached to individual nerves. If successful, this approach offers the potential for a new therapeutic modality alongside traditional medicines and vaccines.

“This agreement with Verily to establish Galvani Bioelectronics signals a crucial step forward in GSK’s bioelectronics journey, bringing together health and tech to realise a shared vision of miniaturised, precision electrical therapies. Together, we can rapidly accelerate the pace of progress in this exciting field, to develop innovative medicines that truly speak the electrical language of the body.”

Brian Otis, Verily’s Chief Technology Officer, said: “This is an ambitious collaboration allowing GSK and Verily to combine forces and have a huge impact on an emerging field. Bioelectronic medicine is a new area of therapeutic exploration, and we know that success will require the confluence of deep disease biology expertise and new highly miniaturised technologies.

“This partnership provides an opportunity to further Verily’s mission by deploying our focused expertise in low power, miniaturised therapeutics and our data analytics engine to potentially address many disease areas with greater precision with the goal of improving outcomes.”

Galvani Bioelectronics will be headquartered within GSK’s global R&D centre at Stevenage in the UK, with a second research hub at Verily’s facilities in South San Francisco. It will initially employ around 30 expert scientists, engineers and clinicians, and will fund and integrate a broad range of collaborations with both parent companies, academia and other R&D companies. GSK and Verily believe this collaborative way of working will rapidly accelerate the development of bioelectronic medicines.

Kris Famm, GSK’s Vice President of Bioelectronics R&D, has been appointed President of the new company. Famm has pioneered work in both large and small molecule drug discovery and worked for a decade developing and delivering R&D strategy with a recurring focus on emerging technologies. He has co-designed and led GSK’s exploration of bioelectronics.  A seven-member board, chaired by Moncef Slaoui, will also be appointed and will include Andrew Conrad, CEO of Verily. The new company will be fully consolidated in GSK's financial statements.

This agreement is subject to customary closing conditions (including requisite antitrust approvals) and is expected to close before the end of 2016.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

Living by a forest diversifies kid’s micronutrient intake, study finds

17 Aug 2018 --- A global study has found that children who live near forests enjoy a better nutrition intake than those who live further away from them. The research, which was conducted across 27 developing countries, identified that children living by forests had at least 25 percent greater diversity in their diets compared to kids who did not. The study, published in Science Advances, notes particular nutrient increases with vitamin A and iron. The findings have the potential for actors attempting to lessen malnutrition through interventions such as fortification, by highlighting the benefit that could come from an integrated approach.

Health & Nutrition News

Low-carb diets could shorten life by four years, warns Lancet study

17 Aug 2018 --- Following a low-carb diet could shorten life expectancy by four years, suggests new research published in The Lancet Public Health. The high levels of animal fats and proteins that often replace carbohydrates in typical low-carb diets appear to be associated with the higher risk of mortality. Eating more plant-based proteins and fats in place of carbohydrates was linked to lower mortality and even reversed the greater mortality risk. 

Health & Nutrition News

Weekly Roundup: US consumers rank clean water as top health desire, high protein diet reduces risk of diabetes for those with fatty liver

17 Aug 2018 --- The weekly roundup is NutritionInsight's collection of global nutrition stories from the past week. A Nestlé Waters commissioned survey found that clean water is the most important health factor to US consumers and a study found that increasing the amount of protein in the diet may reduce the risk of diabetes in people with Non-Alcoholic Fatty Liver Disease (NAFLD). Australia based Freedom Foods acquired protein product brand Crankt to strengthen its position in the sports nutrition market. The European Commission (EC) approved an application from DSM Europe to rename the carotenoid zeaxanthin in the novel food register. CBI and Campden BRI are teaming up for a Colombian product development workshop and, lastly, the Council for Responsible Nutrition (CRN) announced eleven new additions to its membership ranks.

Health & Nutrition News

Molecular switch may serve as new target point for obesity and diabetes therapies, says study

16 Aug 2018 --- A mechanism of the PI3KC2A kinase enzyme may have significance for the future development of therapies against cancer, obesity and diabetes, research published in Molecular Cell has found. The study highlights how if specific signaling cascades are misregulated, diseases and metabolic disorders may occur. The identified mechanism may have a crucial influence on such signaling cascades.

Health & Nutrition News

ADM strengthens gut health strategy with US$235m Probiotics International acquisition

16 Aug 2018 --- Adding to a list of microbiome strategy investments, Archer Daniels Midland Company (ADM) has completed its acquisition of Probiotics International Limited (PIL) – known under its umbrella brand Protexin – in a US$235 million deal.

More Articles
URL : http://www.nutritioninsight.com:80/news/glaxosmithkline-and-alphabet-create-715-million-bioelectronics-firm.html